
|Videos|October 5, 2022
Neoadjuvant Chemotherapy as Standard-of-Care for Muscle-Invasive Urothelial Carcinoma
Srikala Sridhar, MD, MSc, FRCPC, explains the importance of neoadjuvant cisplatin-based chemotherapy and why bladder-sparing treatments should be considered for all patient populations.
Advertisement
Episodes in this series

Advertisement
Related to this article

Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA approved nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with high-grade papillary-only tumors.
Advertisement
Advertisement
Trending on OncLive
1
VOLGA, DASL-HiCaP Data Highlight Key Genitourinary Cancer Presentations Arriving at ESMO 2026
2
Stay Ahead of ESMO 2026: See What Lung Cancer Experts Are Prioritizing
3
CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
4
Lifileucel Linked to Low Rates of Post-Discharge Severe TRAEs, Readmissions in Advanced Melanoma
5



